Medicaid cuts GLP‑1 coverage
Pennsylvania’s Medicaid program has stopped covering GLP‑1s for obesity after costs ballooned from $233 million to $1.3 billion over three years, a move that highlights how quickly public budgets can be strained by new therapies (inquirer.com). For patients, that means access is becoming inconsistent across payers — expect more local policy fights and coverage caveats in the months ahead (inquirer.com).
Pennsylvania’s Medicaid program spent about $233 million on glucagon-like peptide-1 drugs in 2022 and about $1.3 billion in 2025, then ended coverage on January 1, 2026 for adults using those drugs only for overweight or obesity. (pa.gov) (msn.com) These drugs were originally built for type 2 diabetes, where they help the body release insulin and slow digestion, and later versions like Wegovy and Zepbound won approval for obesity treatment too. (phlp.org) Pennsylvania only started covering glucagon-like peptide-1 drugs for obesity in January 2023, so the state went from zero years of that benefit to shutting it down in three budget cycles. (pa.gov) The legal wrinkle is that Medicaid usually has to cover almost every Food and Drug Administration approved drug, but weight-loss drugs sit in a carveout that lets states say no. (kff.org) (pa.gov) That is why access to the same injection now depends on what diagnosis is written on the chart: Pennsylvania still covers these medicines for conditions other than overweight or obesity if a new prior authorization shows medical necessity. (healthpartnersplans.com) (pa.gov) Pennsylvania is not an outlier on coverage. Kaiser Family Foundation said in January 2026 that only 13 state Medicaid fee-for-service programs covered glucagon-like peptide-1 drugs for obesity treatment. (kff.org) The price problem is simple arithmetic: a drug that can cost more than $1,000 a month at list price can blow through a public insurance budget fast when tens of thousands of people want it for a chronic condition that often requires long-term use. (wegovy.com) (kff.org) Drug rebates soften some of that bill for Medicaid, but they do not erase it, and Pennsylvania’s spending curve still rose by roughly a billion dollars in three years even before the state reversed course. (msn.com) (pa.gov) For patients, the result is a patchwork where a person with employer insurance, a person on Medicaid, and a person on Medicare can all face different rules for the same obesity drug. Medicare still does not generally cover drugs used only for obesity under current law, and many private plans restrict them too. (kff.org) So the fight is moving from the doctor’s office to state budgets and benefit design. Pennsylvania’s cutoff shows that once a breakthrough drug moves from a small diabetes population to a much larger obesity population, the question stops being whether the medicine works and turns into who will pay for it. (kff.org) (pa.gov)
